A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Naveen Pemmaraju , Giovanni Marconi , Elisabetta Todisco , Pau Montesinos (1, 2) , Andrew A. Lane , Kendra Sweet , Eunice S. Wang , Eric Deconinck (3, 4) , David A. Rizzieri , Roland B. Walter , Ahmed Aribi , Delphine Lebon (5, 6) , Moshe Y. Levy , Luca Mazzarella (7) , Giovanni Martinelli , Federica Gigli , Harry P. Erba , Evelyn Acuna-Cruz , Marina Konopleva (8) , Hagop Kantarjian , Callum M. Sloss , Jiuzhou Wang , Kara E. Malcolm , Patrick A. Zweidler-Mckay , Daniel J. Deangelo , Naval Daver

1 Hospital Universitari i Politècnic La Fe = University and Polytechnic Hospital La Fe
2 ISC - Instituto de Salud Carlos III [Madrid]
3 Hôpital JeanMinjoz
4 CHRU Besançon - Centre Hospitalier Régional Universitaire de Besançon
5 CHU Amiens-Picardie
6 HEMATIM - HEMATIM - Hématopoïèse et immunologie - UR UPJV 4666
7 DEI - Dipartimento di Ingegneria de l'Informazione [Padova]
8 MD Anderson Cancer Center [Houston]

Domaines: Médecine humaine et pathologie

Naveen Pemmaraju, Giovanni Marconi, Elisabetta Todisco, Pau Montesinos, Andrew A. Lane, et al.. A Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, for Patients with Frontline and Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood, 2021, 138 (1), ⟨10.1182/blood-2021-146681⟩. ⟨hal-03778933⟩